Jones Trading Lowers Capricor Therapeutics (NASDAQ:CAPR) Price Target to $29.00

Capricor Therapeutics (NASDAQ:CAPR - Free Report) had its target price reduced by Jones Trading from $40.00 to $29.00 in a research note published on Wednesday,Benzinga reports. Jones Trading currently has a buy rating on the biotechnology company's stock.

Several other equities analysts have also commented on CAPR. HC Wainwright reiterated a "buy" rating and issued a $77.00 target price on shares of Capricor Therapeutics in a research note on Tuesday. Wall Street Zen lowered shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Oppenheimer decreased their target price on shares of Capricor Therapeutics from $43.00 to $22.00 and set an "outperform" rating on the stock in a research report on Monday. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $30.00 price target on shares of Capricor Therapeutics in a research report on Wednesday, May 14th. Finally, Roth Capital reaffirmed a "buy" rating and set a $31.00 price target on shares of Capricor Therapeutics in a research note on Tuesday, June 17th. One analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. According to MarketBeat, Capricor Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $33.75.

Capricor Therapeutics Trading Up 1.3%

Shares of Capricor Therapeutics stock traded up $0.13 during mid-day trading on Wednesday, hitting $10.18. 1,848,673 shares of the stock were exchanged, compared to its average volume of 1,966,904. The stock has a market capitalization of $465.02 million, a price-to-earnings ratio of -7.17 and a beta of 0.84. Capricor Therapeutics has a twelve month low of $3.52 and a twelve month high of $23.40. The company has a 50-day simple moving average of $10.89 and a 200 day simple moving average of $12.38.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.20). The firm had revenue of $2.73 million for the quarter, compared to analyst estimates of $3.16 million. Capricor Therapeutics had a negative return on equity of 62.42% and a negative net margin of 181.71%. During the same quarter last year, the business posted ($0.31) EPS. Equities research analysts forecast that Capricor Therapeutics will post -1.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Capricor Therapeutics

Several large investors have recently made changes to their positions in the business. Summit Investment Advisors Inc. lifted its holdings in shares of Capricor Therapeutics by 54.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock valued at $53,000 after acquiring an additional 1,345 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Capricor Therapeutics by 172.8% during the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock worth $64,000 after purchasing an additional 2,947 shares in the last quarter. Virtus ETF Advisers LLC acquired a new position in shares of Capricor Therapeutics during the fourth quarter worth about $68,000. AlphaQuest LLC purchased a new stake in shares of Capricor Therapeutics in the fourth quarter worth about $78,000. Finally, New York State Common Retirement Fund grew its stake in shares of Capricor Therapeutics by 625.0% in the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock valued at $80,000 after buying an additional 5,000 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company's stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.